The Zacks Consensus Estimate for Merck’s Pharmaceutical unit is $14.96 billion, while our estimate is $14.8 billion. In the ...

Merck Animal Health, a division of Merck & Co., Inc., Rahway, New Jersey, has introduced SENSEHUB Dairy Youngstock, the industry’s first monitoring technology for dairy calves from birth ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...

Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing ... following table reflects sales of the company’s top products and significant performance drivers.

Zoetis' Livestock segment offers products for reproductive diseases in ... vaccine development and manufacturing capabilities. Merck & Co., Inc. (US) Merck & Co., Inc. is a global healthcare ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Oct 17 (Reuters) - (This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the headline and paragraphs 1 and 2) Merck (MRK.N), opens ...

Merck MRK will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively.